Omeros Drops Dives Over 41% On Bad FDA Data (OMER)

by Benzinga Staff
March 31, 2011 4:49 PM | 11 seconds read |
Omeros OMER dives over 41% in post-market trading after the company reported disappointing endpoint results. The resumption alert can be found here. The data can be found here.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!